Literature DB >> 19402383

Expression of immunomodulating genes in prostate cancer and benign prostatic tissue.

Anca Reschner1, Helena Harlin, Brett Laven, Fredrik Eriksson, Pavel Pisa, Lars Egevad.   

Abstract

OBJECTIVE: To investigate the expression of immunomodulating genes in prostate cancer and benign prostatic tissue. STUDY
DESIGN: We investigated by quantitative real-time polymerase chain reaction the expression of indoleamine 2,3-dioxygenase, arginase 1, arginase 2, inducible form of nitric oxide synthase, cyclooxygenase 2 (COX-2), programmed death ligand 1 and interleukin 10 in 36 matched pairs of samples from prostate cancer and benign prostatic tissue.
RESULTS: Among the genes analyzed, arginase 2 and COX-2 showed statistically significant up-regulation and down-regulation, respectively, in malignant compared to benign prostate tissue. In addition, arginase 1 was more often present in cancer than benign samples. No significant modulation was detected for the other genes under investigation.
CONCLUSION: Our data suggest that arginine metabolism may be involved in prostate cancer immune response evasion, whereas COX-2 may play a role in pathogenesis. We provide a snapshot of immunosuppressive gene expression at the transcriptional level in the prostate tumor microenvironment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19402383

Source DB:  PubMed          Journal:  Anal Quant Cytol Histol        ISSN: 0884-6812            Impact factor:   0.302


  3 in total

1.  Blood and tissue nitric oxide and malondialdehyde are prognostic indicators of localized prostate cancer.

Authors:  Meltem Ozlen Dillioglugil; Haluk Mekık; Bahar Muezzinoglu; T Alp Ozkan; Cennet Gural Demir; Ozdal Dillioglugil
Journal:  Int Urol Nephrol       Date:  2012-06-19       Impact factor: 2.370

Review 2.  Arginine and Arginases Modulate Metabolism, Tumor Microenvironment and Prostate Cancer Progression.

Authors:  Andreia Matos; Marcos Carvalho; Manuel Bicho; Ricardo Ribeiro
Journal:  Nutrients       Date:  2021-12-16       Impact factor: 5.717

3.  Gene therapy with RALA/iNOS composite nanoparticles significantly enhances survival in a model of metastatic prostate cancer.

Authors:  Cian M McCrudden; John W McBride; Joanne McCaffrey; Emma M McErlean; Nicholas J Dunne; Vicky L Kett; Jonathan A Coulter; Tracy Robson; Helen O McCarthy
Journal:  Cancer Nanotechnol       Date:  2018-06-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.